某三甲医院周边区域妇女宫颈HPV感染状况及相关风险因素

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (938 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨某三甲医院周边区域妇女宫颈HPV感染状况及相关风险因素。方法选取常住在武警特色医学中心周边10 km以内,并于2020-01至2023-07在该中心妇科门诊自然就诊的妇女为研究对象,通过问卷调查、宫颈上皮脱落细胞HPV分型检测,对HPV感染状况及与感染相关因素进行统计学分析。结果该中心周边区域自然就诊的女性共入选5967名,宫颈HPV感染1122例,感染率为18.80%,其中单一感染占78.61%(882/1122),多重感染占21.39%(240/1122)。多重感染包括2～5种HPV亚型的混合感染,其中双重感染率2.77%(165/5967),三重感染率1.06%(63/5967),四重感染率0.15%(9/5967),五重感染率0.05%(3/5967)。HPV高危型单一感染率12.42%(741/5967),HPV低危型单一感染率2.36%(141/5967)。感染率由高到低排名前5位的依次为52型(3.17%)、16型(2.92%)、53型(2.66%)、58型(1.66%)、56型(1.46%)。既往性伙伴个数(OR 1.559, 95%CI 1.409～1.724)和初次性生活年龄(OR 0.820, 95%CI 0.707～0.952)是HPV感染的相关风险因素。结论该区域内自然就诊的妇女感染HPV亚型有自身特点,以单一感染为主,HPV型别以52型、16型、53型、58型和56型为主,既往性伙伴人数和初次性生活年龄是HPV感染的相关风险因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	邢青青
	董渠龙
	胡梦颖
	陈晓
	薛红芳
	张岩

关键词 ：人乳头瘤病毒, 感染亚型, 风险因素, 宫颈癌, HPV疫苗

Abstract：Objective To explore the cervical HPV infection status and related risk factors among women in the vicinity of a 3A hospital. Methods The women who resided around Characteristics Medical Center of Chinese People’s Armed Police Force and naturally visited the gynecological outpatient department from January 2020 to July 2023 were selected as the study subjects. Through questionnaire survey and detection of HPV typing of cervical epithelial exfoliated cells, HPV infection status and related factors were statistically analyzed. Results A total of 5967 women were selected, and 1122 cases were infected with cervical HPV, with HPV infection rate of 18.80% (1122/5967), of which single infection accounted for 78.61% (882/1122) and multiple infections accounted for 21.39% (240/1122). Multiple infections include mixed infections of 2 to 5 HPV subtypes, with a dual infection rate of 2.77% (165/5967), triple infection rate of 1.06% (63/5967), quadruple infection rate of 0.15% (9/5967), and quintuple infection rate of 0.05% (3/5967). The single infection rate of high-risk HPV was 12.42% (741/5967), and the single infection rate of low-risk HPV was 2.36% (141/5967). The top 5 infection rate from high to low were HPV 52 (3.17%), HPV 16 (2.92%), HPV 53 (2.66%), HPV 58 (1.66%) and HPV 56 (1.46%). The number of previous sexual partners (OR 1.559, 95%CI 1.409-1.724) and age of first sexual intercourse (OR 0.820, 95%CI 0.707-0.952) were related risk factors for HPV infection. Conclusions The HPV subtypes among the women who naturally seek medical treatment in this region have their own characteristics, mainly single infection, and the HPV types were mainly 52, 16, 53, 58, and 5. The number of previous sexual partners and the age of first sexual intercourse are related risk factors for HPV infection.

Key words： human papilloma virus infection subtype risk factor cervical cancer HPV vaccine

收稿日期: 2023-11-25

ZTFLH:

R713

通讯作者: 陈晓,E-mail:Cx78130 @126.com

作者简介: 邢青青,本科学历,护师。

引用本文:

邢青青, 董渠龙, 胡梦颖, 陈晓, 薛红芳, 张岩. 某三甲医院周边区域妇女宫颈HPV感染状况及相关风险因素[J]. 武警医学, 2024, 35(7): 588-592. XING Qingqing, DONG Qulong, HU Mengying, CHEN Xiao, XUE Hongfang, ZHANG Yan. Analysis of cervical HPV infection status and related risk factors among women in the vicinity of a 3A hospital. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(7): 588-592.

链接本文:

https://journal08.magtechjournal.com/Jwk_wjyx/CN/ 或 https://journal08.magtechjournal.com/Jwk_wjyx/CN/Y2024/V35/I7/588

[1]	李道娟,师金,靳晶,等.宫颈癌的流行病学趋势[J].中华肿瘤杂志,2021,43(9): 912-916.
[2]	Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[3]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68(6):394-424.
[4]	Revathidevi S, Murugan A K, Nakaoka H, et al. APOBEC: a molecular driver in cervical cancer pathogenesis[J]. Cancer Lett, 2021, 496: 104-116.
[5]	Ntanasis-Stathopoulos I, Kyriazoglou A, Liontos M, et al. Current trends in the management and prevention of human papillomavirus (HPV) infection[J]. J BUON, 2020, 25(3): 1281-1285.
[6]	Brianti P, de Flammineis E, Mercuri S R. Review of HPV-related diseases and cancers[J]. New Microbiol, 2017, 40(2): 80-85.
[7]	李明珠,魏丽惠.HPV的致瘤机制及以此预防HPV感染的研究进展[J].中华妇产科杂志,2022,57(2):152-155.
[8]	Dunne E F, Park I U. HPV and HPV-associated diseases[J]. Infect Dis Clin North Am, 2013, 27(4):765-778.
[9]	Giuliano A R, Nyitray A G, Kreimer A R, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection [J]. Int J Cancer, 2015, 136(12):2752-2760.
[10]	Kombe Kombe A J, Li B, Zahid A, et al. Epidemiology and burden of human papillomavirus and related diseases, molecular pathogenesis, and vaccine evaluation[J]. Front Public Health, 2021, 8: 552028.
[11]	岑尧,张翠英,张雅丽,等.中国女性人乳头瘤病毒感染状况及高危型别分布的Meta分析[J].癌症进展,2013,11(1):75-81.
[12]	Zhang Y, Wang Y, Liu L, et al. Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China [J]. Oncotarget, 2016, 7(38):62411-62424.
[13]	Wang Y, Meng Y, Li W, et al. Prevalence and characteristics of hrHPV infection among 414,540 women: a multicenter study in central and eastern China [J]. J Cancer, 2019, 10(8):1902-1908.
[14]	Tang Y, Zheng L, Yang S, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in Southwest China: a cross-sectional five years study in non-vaccinated women [J]. Virol J, 2017, 14(1): 84.
[15]	石芳,赵建芳.延安地区女性宫颈HPV感染特征及基因分型研究[J].延安大学学报(医学科学版),2021,19(3):55-58.
[16]	何英杰,王海波,祁志宇.承德地区HPV感染影响多因素及不同治疗方法干预效果分析[J]. 中国公共卫生杂志,2020,36(4):619-622.
[17]	宫迎迎,周烨,韩辉,等.济宁地区自然就诊妇女宫颈HPV感染型别调查及HR-HPV持续性感染危险因素分析[J].中华肿瘤防治杂志,2020,27(21): 1698-1702.
[18]	曹杰贤,李雪菲,沈国玲,等.云南7个地区女性HPV亚型感染情况调查[J].检验医学与临床,2021,18(6):789-792.
[19]	陈秀杰,王嫱,王雅楠,等.宫颈HPV感染状况及其与宫颈柱状上皮异位的相关性研究[J].国际妇产科学杂志,2021,48(6):710-714.
[20]	马丁,魏丽惠,谢幸,等.人乳头瘤病毒疫苗临床应用中国专家共识[J].协和医学杂志,2021,12(2):189-201.
[21]	李甜甜,武丽,吕霄,等.人乳头瘤病毒的感染现况及免疫治疗研究进展[J].实用医学杂志,2019,35(18):2862-2867.